Sector News

Merck KGaA in advanced talks to sell off biosims unit

March 10, 2017
Life sciences

The rumors are true: When it comes to biosimilars, Merck KGaA has had enough.

The German drugmaker is in advanced negotiations to sell its unit of biologic copycats, it said in its 2016 annual report (PDF).

The confirmation follows an October report from Reuters that the company had brought on JPMorgan Chase & Co. to help it scout potential buyers for the business. Sources at the time said it could fetch up to $1 billion.

Merck has been collaborating with Indian generics maker Dr. Reddy’s on biosimilars development since 2012, but the team has yet to bring a product to market. Its pipeline includes a copy of AbbVie’s Humira currently in phase 3 testing.

Many of the company’s rivals are further along: Novartis’ Sandoz and Pfizer already have biosimilars on the scene in the U.S., and Amgen’s Humira copy is awaiting launch following a September FDA approval. And as the market begins to crowd, companies still playing catch-up may have to slash prices to nab a piece of the pie. That wouldn’t be good for the latecomers and their revenue prospects—and it would drag down the sales potential for earlier-to-market meds, too.

Merck KGaA isn’t the only drugmaker trying to bail on biosims. Late last month, Allergan CEO Brent Saunders told Bloomberg his company would likely do the same after it wraps up the four cancer-drug copies it’s currently developing with Amgen.

Meanwhile, biosimilars may not be the only unit Merck bids farewell in the near future. Each of the company’s divisions is under an ongoing review, CEO Stefan Oschmann told reporters Thursday, according to Reuters.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach